Holen Sie sich die Stockscreener-App
4.61
0.00%
0.00
Exicure Inc Aktie (XCUR) Neueste Nachrichten
Exicure, Inc. Reports 2025 Financial Results and Highlights Urgent Need for Additional Financing After GPCR USA Acquisition - Minichart
Exicure, Inc. 2025 Annual Report: Strategic Alternatives, Financial Results, and Risk Factors Overview - Minichart
Exicure 10-K: Revenue $0.0M, EPS $(0.79) — net loss narrows to $(4.95)M - TradingView
Exicure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Exicure (NASDAQ: XCUR) flags going concern, legal and listing risks - Stock Titan
Liquidity strain deepens as Exicure (NASDAQ: XCUR) posts 2025 results - Stock Titan
Exicure, Inc. Reports 2025 Financial Results and Highlights Need for Additional Financing - Quiver Quantitative
Exicure, Inc. Reports Full Year 2025 Financial Results - Bitget
Casella Waste Systems, Inc. to Present at Upcoming Investor Conference - The Manila Times
Exicure says its cash won't fund the next 12 months of operations - Stock Titan
Portfolio Update: Can Exicure Inc expand into new marketsWatch List & Technical Entry and Exit Tips - baoquankhu1.vn
Breakout Zone: Does Exicure Inc offer margin of safetyMarket Performance Report & High Conviction Buy Zone Alerts - baoquankhu1.vn
Exicure Inc Stock (ISIN: US30205M1027) Faces Uncertainty Amid Biotech Sector Volatility - AD HOC NEWS
Short Interest in Exicure, Inc. (NASDAQ:XCUR) Rises By 14.3% - Defense World
Pharma News: What is the Moat Score of Exicure IncEarnings Risk Summary & High Accuracy Trade Alerts - baoquankhu1.vn
Aug Catalysts: Is Exicure Inc stock influenced by commodity prices2026 Retail & Daily Profit Maximizing Tips - baoquankhu1.vn
(XCUR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Can Exicure Inc continue delivering strong returnsTrade Entry Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
Breakout Watch: Whats the fair value of Exicure Inc stockTreasury Yields & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Trend Review: Is Exicure Inc stock a hidden gemDay Trade & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Activity Recap: Can Exicure Inc continue delivering strong returnsLayoff News & Fast Moving Market Watchlists - baoquankhu1.vn
(XCUR) Risk Channels and Responsive Allocation - Stock Traders Daily
XCUR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
David Giljohann - Crain's Chicago Business
XCUR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Exicure (XCUR) CAO has shares withheld to cover RSU taxes - Stock Titan
Exicure Announces New CEO and Interim CFO Appointments - The Globe and Mail
Bear Alert: Whats the fair value of Exicure Inc stockFed Meeting & AI Driven Price Forecasts - baoquankhu1.vn
Can Exicure Inc. continue delivering strong returnsWeekly Trade Summary & Weekly High Return Opportunities - mfd.ru
Market Pulse: Does Exicure Inc stock have upside surprise potentialJuly 2025 WrapUp & Smart Allocation Stock Reports - baoquankhu1.vn
Exicure announces board and executive changes, CEO and CFO resignations By Investing.com - Investing.com India
Exicure announces board and executive changes, CEO and CFO resignations - Investing.com Nigeria
Exicure Announces Major Leadership and Board Restructuring - TipRanks
Leadership shake-up at Exicure (NASDAQ: XCUR) as CEO, CFO and directors exit - Stock Titan
Why Exicure Inc. stock remains on watchlistsJuly 2025 Trends & Technical Pattern Recognition Alerts - mfd.ru
Can Exicure Inc. stock sustain revenue growth2025 Stock Rankings & Accurate Buy Signal Alerts - mfd.ru
Aug Intraday: What is the Moat Score of Exicure IncTrade Risk Summary & Capital Protection Trading Alerts - baoquankhu1.vn
Exicure announces publication of results from Phase 2 study of burixafor - TipRanks
Exicure (XCUR) Publishes Promising Phase 2 Study Results for Bur - GuruFocus
Exicure (XCUR) Publishes Promising Phase 2 Study Results for Burixafor - GuruFocus
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant - The Manila Times
Exicure, Inc. Publishes Phase 2 Study Results for Burixafor, a Novel CXCR4 Inhibitor in Hematologic Disease Treatment - Quiver Quantitative
Same-day stem cell collection seen in Exicure Phase 2 cancer trial - Stock Titan
Market Catalysts: Can Exicure Inc expand into new marketsJuly 2025 Chart Watch & High Conviction Buy Zone Picks - baoquankhu1.vn
Quarterly Earnings: Should I invest in NEPH before earningsWeekly Market Outlook & Daily Profit Maximizing Tips - baoquankhu1.vn
Jobs Data: Does Exicure Inc offer margin of safetyGap Up & Verified Entry Point Detection - baoquankhu1.vn
Trade Report: What is the Moat Score of Exicure Inc2025 Sector Review & Trade Opportunity Analysis - baoquankhu1.vn
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up - TipRanks
Market Trends: What is the Moat Score of Exicure IncJuly 2025 Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Exicure completes Phase 2 trial milestone and plans $1 million payment to GPCR Therapeutics - Investing.com UK
Exicure to Pay GPCR Therapeutics $1 Million for First Milestone Completion - 아시아경제
Exicure Achieves Milestone in Burixafor Phase 2 Program - TipRanks
Exicure Achieves First Milestone in Collaboration with GPCR Therapeutics - TradingView
Exicure to present phase 2 burixafor data at 2026 transplantation meeting - Investing.com Nigeria
Major Exicure Stakeholder Makes Bold Move With Large Share Sale - TipRanks
0.99%
3.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):